The Kim Laboratory - SPIN-OFFS & VENTURES

SPIN-OFFS & VENTURES

FROM BENCH TO BOARDROOM: ARCHITECTING PLATFORM BIOTECHS

We do not incubate incremental improvements; we engineer systemic disruption. The Kim Laboratory operates as a high-velocity venture incubator. We recognize that the ultimate validation of our 'Human-Twin' systems genetics and AI-native platforms is their commercialization. Therefore, our most disruptive IP assets are designed from inception to spin out into dominant, standalone therapeutics companies. We invite top-tier venture capital, life science syndicates, and strategic funds to access our pipeline of pre-de-risked, stealth-stage ventures before they hit the open market.

THE UNFAIR ADVANTAGE: PRE-DE-RISKED ASSETS

The foundational flaw of early-stage biotech investing is catastrophic translational risk—assets that cure C57BL/6 mice but fail in human trials. Our spin-offs bypass this illusion entirely. Every asset graduating from our ecosystem has been relentlessly stress-tested through our Diversity Outbred (DO) cohorts and multi-omics AI engines. When you invest in a Kim Lab spin-off, you are backing an asset whose human phenotypic variability, toxicity, and efficacy have been mathematically predicted and biologically validated in a Human-Twin environment. We offer VCs unprecedented predictive certainty prior to Series A.

INCUBATING VENTURES: OUR PROPRIETARY PIPELINE

(The following projects are currently undergoing rigorous IP landscaping and IND-enabling validation, preparing for imminent spin-off.)

Venture I: Project Evergreen (Stealth)

Modality: Precision Postbiotics (PV-derived Cyclopeptide)
Target Market: Muscle Preservation in the GLP-1 Era & Sarcopenia (Massive TAM)
The Thesis: The $100B GLP-1 weight-loss market is facing a critical bottleneck: severe muscle attrition. Project Evergreen isolates definitively structured postbiotic cyclopeptides that mechanistically halt muscle degradation and reverse inflammaging via the Gut-Muscle Axis. This is the ultimate partner therapeutic for next-generation obesity and longevity drugs.
Status: Lead optimization complete; Human-Twin in vivo validation ongoing; Core composition-of-matter IP filing in progress.

Venture II: Project Challenger (Stealth)

Modality: Targeted Small Molecule / Receptor Inhibitor (ALK7)
Target Market: Cancer Cachexia & Oncology Combo-Therapeutics
The Thesis: Cancer cachexia remains a profound unmet medical need with zero FDA-approved therapeutics. Project Challenger leverages ALK7 inhibition to not only reverse severe muscle wasting but also orchestrate a 'Cold-to-Hot' immune transition within the Tumor Microenvironment (TME). This dual-action mechanism offers a paradigm-shifting combination therapy for solid tumors.
Status: Mechanistic Proof-of-Concept (PoC) secured; In vitro biased signaling validated; In vivo survival cohort modeling active.

Venture III: The IDDS Platform (Platform-as-a-Service Spin-off)

Modality: AI-Native De-risking & Predictive Engine
Target Market: B2B Pharma SaaS & Precision Longevity Clocks
The Thesis: Moving beyond drug assets, this venture commercializes the Kim Lab’s core infrastructure. By monopolizing the proprietary dataset of our 300+ DO Mouse Cohort integrated with deep multi-omics and Lab-AGI, this platform acts as an Oracle for clinical success. It offers global pharma an exclusive subscription to de-risk their pipelines before initiating Phase 1.
Status: Database architecture established; Algorithmic training via multi-omics factor analysis (MOFA) advancing.

SECURE YOUR ALLOCATION (EARLY-STAGE DEAL SOURCING)

We are actively syndicating our early-stage ventures. For VC partners, institutional investors, and biotech incubators seeking access to structurally de-risked assets with multi-billion-dollar TAMs, we offer exclusive technical briefings under NDA.

Partner with us at the inception phase to secure foundational stakes in the therapeutics of tomorrow.

Target Investment Stages: Seed / Pre-Series A / Strategic Joint Ventures
Contact: Chief Architect & PI, Dr. Myungsuk Kim

INITIATE VC CONFIDENTIAL BRIEFING